Delving into the Latest Updates on Thymoquinone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

Mechanism

E2F1 inhibitors(Transcription factor E2F1 inhibitors), MUC4 inhibitors(mucin 4, cell surface associated inhibitors), PTEN stimulators(PTEN stimulators)

Therapeutic Areas

Infectious DiseasesMouth and Tooth DiseasesNeoplasms+ [8]

Active Indication

GingivitisHormone receptor positive breast cancerNon-Small Cell Lung Cancer+ [8]

Inactive Indication-

Originator Organization

The Case Comprehensive Cancer Center

Active Organization

Beni-Suef University

Barbara Ann Karmanos Cancer Institute

University of Miami

+ [13]

Inactive Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H12O2

InChIKeyKEQHJBNSCLWCAE-UHFFFAOYSA-N

CAS Registry490-91-5

Gingival diseases occur commonly in the global population and herbal products for its intervention have limited body of research evidence. This study to evaluate the clinical efficacy of 5% thymoquinone (TQ) gel as an adjunct to scaling and root planing (SRP) in patients diagnosed with gingivitis.
OBJECTIVE: To evaluate the efficacy of 5% TQ gel using a novel liposome drug delivery as a topical application following SRP in gingivitis patients.
DESIGN: Double-blinded, parallel, randomized controlled clinical trial. SETTING: Faculty of Dentistry, King Abdulaziz University, and Qassim University, Saudi Arabia

Start Date01 Sep 2022

Sponsor / Collaborator

King Abdulaziz University

100 Clinical Results associated with Thymoquinone

Login to view more data

100 Translational Medicine associated with Thymoquinone

Login to view more data

100 Patents (Medical) associated with Thymoquinone

Login to view more data

1,753

Literatures (Medical) associated with Thymoquinone

01 Jan 2025·Current Drug Delivery

Nigella sativa Oil-loaded Ethanolic Vesicular Gel for Imiquimod-induced Plaque Psoriasis: Physicochemical Characterization, Rheological Studies, and In vivo Efficacy

Article

Author: Ranjan Lal, Uma ; Kumar Chellappan, Dinesh ; Vihal, Samar ; Rathore, Charul ; Negi, Poonam ; Gupta, Gaurav ; Pundir, Swati ; Kumar Singh, Sachin ; Dua, Kamal

Background:The therapeutic effect of NS oil in mild to moderate psoriasis is limited owing to low play load of thymoquinone (<15 %w/w), irritation, dripping, low viscosity and thus, less contact time on the lesions.Aims::This study aimed at developing and characterizing the ethanolic vesicular hydrogel system of Nigella sativa (NS) oil (NS EV hydrogel) for the enhancement of anti-psoriatic activity.Objective:The objective of this study was to develop NS EV hydrogel and evaluate its anti-psoriatic activity.Methods:The identification and quantification of TQ content in different NS seed extracts and marketed oil were measured by an HPTLC method using n-hexane and ethyl acetate as solvent systems. Preparation of ethanolic vesicles (EVs) was performed by solvent injection method, while its antipsoriatic activity was evaluated employing an Imiquad (IMQ)-induced plaque psoriasis animal model.Results:A compact HPTLC band was obtained for TQ at an Rf value of 0.651. The calibration plot was linear in the range of 1-10 μg/spot, and the correlation coefficient of 0.990 was indicative of good linear dependence of peak area on concentration. From the different NS sources, the high TQ content was obtained in the marketed cold press oil, i.e., 1.45±0.08mg/ml. Out of various NS oilloaded EVs, the F6 formulation revealed the smallest particle size (278.1nm), with log-normal size distribution (0.459) and adequate entrapment efficiency. A non-uniform shape was observed in the transmission electron microscopy. The viscosity of F6 formulation hydrogel was 32.34 (Pa·s), which exhibited plastic behavior. In vivo, efficacy studies demonstrated decreased inflammation of the epidermis and dermis and a marked decrease in the levels of IL-17 by NS EV hydrogel compared to plain NS oil and standard drugs (Betamethasone and Dr. JRK Psorolin Oil).Conclusion:It may be concluded from the findings that NS-loaded EV gel was as good as betamethasone cream but more efficacious than the other treatments.

31 Dec 2024·Journal of Enzyme Inhibition and Medicinal Chemistry

Effects of thymoquinone and the curcumin analog EF-24 on the activity of the enzyme paraoxonase-1 in human glioblastoma cells U87MG

Article

Author: Sunguroglu, Asuman ; Özgültekin, Nurbanu ; Kilic, Ahmet ; Simsek, Ender ; Ozensoy Guler, O

The spices and aromatic herbs were used not only in cooking to add flavour and smell to dishes but also for medicinal use. Nigella sativa, also called black cumin, is one of the species that contains an important bioactive component, thymoquinone (TQ), which has antioxidant, anti-inflammatory, antimicrobial, and antidiabetic effects. Curcuma longa, which also includes curcumin, has numerous anti-cancer properties. However, the bioavailability of curcumin is lower than that of its analogs. An analog of curcumin (EF-24), which has better bioavailability than curcumin, is capable of exerting a high anti-cancer effect. In our study, we determined the effects of PON1 enzyme activity on the proliferation and aggressiveness of glioblastoma cancer treated with TQ and EF-24 from lysates of the glioblastoma cell line U87MG. The results were determined as increased PON1 activity after treatment with TQ and EF-24 in the U87MG cell line (p < 0.0001).

31 Dec 2024·Drug Delivery

Self-micellizing solid dispersion of thymoquinone with enhanced biopharmaceutical and nephroprotective effects

Article

Author: Halder, Shimul ; Shill, Manik Chandra ; Shuma, Madhabi Lata ; Sharmin, Nahid ; Afrose, Sanjida ; Rahman, S M Abdur ; Mollick, Patricia Prova ; Muhit, Md Abdul

The present study was designed to develop a self-micellizing solid dispersion (SMSD) containing Thymoquinone (TQM), a phytonutrient obtained from Nigella sativa seeds, aiming to improve its biopharmaceutical and nephroprotective functions. The apparent solubility of TQM in polymer solutions was used to choose an appropriate amphiphilic polymer that could be used to make an SMSD system. Based on the apparent solubility, Soluplus® was selected as an appropriate carrier, and mixing with TQM, SMSD-TQM with different loadings of TQM (5-15%) was made by solvent evaporation and freeze-drying techniques, respectively, and the formulations were optimized. The optimized SMSD-TQM was evaluated in terms of particle size distribution, morphology, release characteristics, pharmacokinetic behavior, and nephroprotective effects in a rat model of acute kidney injury. SMSD-TQM significantly improved the dissolution characteristics (97.8%) of TQM in water within 60 min. Oral administration of SMSD-TQM in rats exhibited a 4.9-fold higher systemic exposure than crystalline TQM. In a cisplatin-induced (6 mg/kg, i.p.) acute kidney-damaged rat model, oral SMSD-TQM (10 mg/kg) improved the nephroprotective effects of TQM based on the results of kidney biomarkers and histological abnormalities. These findings suggest that SMSD-TQM might be efficacious in enhancing the nephroprotective effect of TQM by overcoming biopharmaceutical limitations.

100 Deals associated with Thymoquinone

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gingivitis	Phase 1	SA	King Abdulaziz University	01 Sep 2022
Primary Effusion Lymphoma	Preclinical	SA	King Faisal Specialist Hospital & Research Centre	01 May 2009
Primary Effusion Lymphoma	Preclinical	US	Robert H. Lurie Comprehensive Cancer Center of Northwestern Un	01 May 2009
Breast Cancer	Preclinical	EG	Al-Azhar University	01 May 2008
Breast Cancer	Preclinical	US	The Ohio State University	01 May 2008
Breast Cancer	Preclinical	EG	Beni-Suef University	01 May 2008
Pancreatic Cancer	Preclinical	US	Barbara Ann Karmanos Cancer Institute	01 May 2008
Pancreatic Cancer	Preclinical	US	The University of Texas MD Anderson Cancer Center	01 May 2008
Prostatic Cancer	Preclinical	US	Henry Ford Hospital	20 Jun 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2017	Not Applicable	Squamous Cell Carcinoma of Head and Neck	-	Cisplatin	svueqpaxzw(vbegpzrrcc) = jifznwgkcn zbddyihqtv (vlzuqaunzt ) View more	-	01 Jul 2017
				Thymoquinone	svueqpaxzw(vbegpzrrcc) = rhffgxtjjb zbddyihqtv (vlzuqaunzt ) View more